Eczema Paratraumatic

Paramatoid eczema includes 2 groups of elements: primary, or eczematoid, and secondary, or pyogenic, developing under the influence of pyogenic microorganisms. Both groups exhibit migration of rash elements, called keratolysis, which leads to the formation of fresh scales and crusts. The disease is accompanied by pain, burning, intense itching, which often results in insomnia. Manifestations of paraovarian eczema are usually observed on exposed parts of the body: in women, the elbows, hands, shins, knees (more often), thighs and face are affected; in men, the armpits, back, buttocks, and face are affected. The rash can spread over more than 80% of the body surface. The elements that predominate are papules, papulosquamosae, and vesicles; when they merge, large blisters with a flaccid red scab are formed. Itching (but not always) increases the severity of the disease, forcing the patient to scratch the skin until it bleeds, forming micro-scratching. Inflammatory vegetations (dermatitis) are localized around the lesion. With the spontaneous extinction of the process, a regression phase begins - lichenification, i.e. thickening of the skin with the formation of dense grayish horny scales, which subsequently fall off and lead to the restoration of skin color against the background of dilated blood vessels. Severe clinical manifestations and resistance to therapy are explained by the addition of secondary flora. An important additional sign of the disease is fever, pain in the joints, muscles (myositis) and mental disorders. The discharge of pus from the lesions contributes to the appearance of edema, so the outcome of the disease is unfavorable even with full treatment. To eradicate the process, systemic therapy is effective, aimed at restoring damaged cells and stabilizing the barrier properties of the skin. Errors in non-treatment cause complications: purulent sycoectenia, boils, eczema of the hands, erythroderma, pyogenic granuloma, erythrodermosis-like rash, etc. Considerable experience has been accumulated in the use of new drugs, but the problem of adapting pharmacotherapy remains difficult.